Patents by Inventor Niels Svenstrup

Niels Svenstrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200157108
    Abstract: The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Inventors: Niels SVENSTRUP, Jun ZHANG, Jikui SUN, Yuyin CHEN, Jianshe KONG, Rujian MA, Junhua ZHANG, Liang QIN, Huanming XIAO, Jinxu SUN, Xiao MENG, Fenglai SUN, Jingyang ZHU
  • Publication number: 20200062770
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Niels SVENSTRUP, Kate WEN, Yazhou WANG
  • Patent number: 10513524
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 24, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Kate Wen, Yazhou Wang
  • Publication number: 20190307754
    Abstract: The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 10, 2019
    Inventors: Niels Svenstrup, Anna I. Parachikova, James McArthur
  • Publication number: 20180194770
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Application
    Filed: July 6, 2016
    Publication date: July 12, 2018
    Inventors: Niels Svenstrup, Kate Wen, Yazhou Wang
  • Patent number: 9993477
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: June 12, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Patent number: 9850249
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 26, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Publication number: 20170173018
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: March 8, 2017
    Publication date: June 22, 2017
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Patent number: 9643970
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 9, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Baek Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgard, Kate Wen, Yazhou Wang
  • Publication number: 20170081333
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: November 22, 2016
    Publication date: March 23, 2017
    Inventors: Niels Svenstrup, Klaus Baiek Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Patent number: 9533992
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 3, 2017
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Patent number: 9434733
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: September 6, 2016
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Patent number: 9434731
    Abstract: The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: September 6, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephan Siegel, Andreas Wilmen, Susanne Röhrig, Niels Svenstrup, Mark Jean Gnoth, Stefan Heitmeier, Ulrich Rester, Adrian Tersteegen, Michael Gerisch
  • Publication number: 20160213674
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: April 4, 2016
    Publication date: July 28, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Publication number: 20150274736
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: October 9, 2012
    Publication date: October 1, 2015
    Inventors: Niels Svenstrup, Klaus Baek Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgard, Kate Wen, Yazhou Wang
  • Patent number: 9051323
    Abstract: The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: June 9, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephan Siegel, Andreas Wilmen, Susanne Röhrig, Niels Svenstrup, Mark Jean Gnoth, Stefan Heitmeier, Ulrich Rester, Dmitry Zubov, Jochen Strayle, Michael Sperzel
  • Publication number: 20150045348
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: January 25, 2013
    Publication date: February 12, 2015
    Applicant: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgärd, Kate Wen, Yazhou Wang
  • Patent number: 8664246
    Abstract: The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: March 4, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephan Siegel, Andreas Wilmen, Niels Svenstrup, Mark Jean Gnoth, Adrian Tersteegen, Ulrich Rester
  • Publication number: 20130296343
    Abstract: The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
    Type: Application
    Filed: April 8, 2013
    Publication date: November 7, 2013
    Inventors: Stephan SIEGEL, Andreas WILMEN, Niels SVENSTRUP, Mark Jean GNOTH, Adrian TERSTEEGEN, Ulrich RESTER
  • Publication number: 20130261115
    Abstract: The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
    Type: Application
    Filed: May 30, 2013
    Publication date: October 3, 2013
    Inventors: Stephan SIEGEL, Andreas WILMEN, Susanne RÖHRIG, Niels SVENSTRUP, Mark Jean GNOTH, Stefan HEITMEIER, Ulrich RESTER, Adrian TERSTEEGEN, Michael GERISCH